Research progress on molecular targeted therapy for metastatic esophageal cancer pa-tients / 中国肿瘤临床

ABSTRACT

Esophageal cancer is a highly aggressive malignant tumor of the digestive tract. Despite the continuous development of sur-gical techniques and multidisciplinary treatments, the prognosis and overall survival of esophageal cancer patients is still poor. In re-cent years, the development of new molecular targeted therapy has become well advanced. Drugs that target tumor-related signal pathways and block the transmission of downstream signals can inhibit the growth and metastasis of tumor cells. Currently, esopha-geal cancer-targeted drugs are rarely approved officially. HER-2 inhibitor represents these types of drugs because of its positive expres-sion of metastatic adenocarcinoma. However, studies on the preparation of new drugs are not extensive. In this paper, the research progress of a new targeted therapy for metastatic esophageal cancer is reviewed.